Self-Assembling Nanovaccine Confers Complete Protection Against Zika Virus Without Causing Antibody-Dependent Enhancement

Heng Rong1,2, Mi Qi1,2, Jingdi Pan1,2, Yuhan Sun1,2, Jiawang Gao1,2, Xiaowei Zhang1, Wei Li1, Bo Zhang1, Xian-En Zhang3 and Zongqiang Cui1,2*

1 State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China, 2 University of Chinese Academy of Sciences, Beijing, China, 3 Faculty of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China

INTRODUCTION

Zika virus (ZIKV) is an arboviral virus belonging to the Flaviviridae family. ZIKV is defined as a serious public health problem by the World Health Organization (WHO) because it is widespread in many countries, with cases of severe birth defects being documented (1, 2). ZIKV also causes severe neurological diseases, such as microcephaly, Guillain–Barré syndrome, meningoencephalitis, and myelitis (3, 4). Although control and preventive measures have been taken, to date, there are no vaccines or specific antiviral drugs against ZIKV.

Several platforms have been tried to develop ZIKV vaccines. For example, live attenuated ZIKV vaccine candidates have been generated by deleting 10 nucleotides in the 3'-untranslated region (UTR) of the ZIKV genome or using the codon pair deoptimization strategy (5). An inactivated full-virus ZIKV vaccine was also developed and induced protection against ZIKV infection (6).
However, attenuated live vaccines have hidden dangers, such as infectious residues, and inactivated ZIKV causes immune-related side effects (7). As the envelope (E) protein and NS1 protein are major targets of host antibody responses, they were also considered candidates for ZIKV vaccines. Li et al. developed an attenuated recombinant vesicular stomatitis virus (rVSV) expressing a ZIKV prM-E-NS1 polyprotein (8). This rVSV could induce ZIKV-specific antibodies and a T cell immune response and protect mice against ZIKV infection. DNA or RNA vaccination based on the ZIKV prM-E gene sequence could also induce strong neutralizing antibodies (NAb) and a T cell immune response and effectively improve the survival rate in mice (9). However, for these candidates, due to the complex preparation processes and stringent storage conditions, there are obstacles limiting large-scale production (10). More importantly, these E protein-based vaccines may cause antibody-dependent enhancement (ADE) and have the potential risk of enhancing other flavivirus infections (11, 12).

The nonneutralizing cross-reactive antibodies generated during a previous flavivirus infection can increase the pathogenesis of a related virus, which is called ADE (13). ADE is particularly common between ZIKV and dengue virus (DENV) (14, 15). ADE is a challenge in vaccine development for flaviviruses, including ZIKV. Approaches to ensure high protective efficacy while avoiding ADE are an important focus in the development of ZIKV vaccines (15). Recently, it was found that ZIKV E protein domain III (zEDIII) can evoke ZIKV-specific antibody and NAb responses without ADE activity for DENV infection (16, 17). Thus, vaccines based on the zEDIII antigen are potential protein subunit vaccine candidates for ZIKV infection. However, the zEDIII subunit has low immunogenicity (18), which limits it to be developed as a protective vaccine.

Self-assembling nanotechnology provides an opportunity for the development of vaccines with superior performance (19–21). Nanoparticles can promote antigen delivery and immune induction (22–25). By presenting the influenza A virus (IAV) trimeric HA or M2e on self-assembling ferritin, nanoparticle vaccines have been developed to confer influenza protection (26). Other nanoparticle vaccines have been tried to prevent Dengue virus and Hepatitis B virus (27, 28). Recently, nanoparticle-based vaccine against SARS-CoV-2 was also reported (29). These nanoparticle vaccines cause more efficacious immune response and protection, which provides a promising strategy for vaccine construction.

In this study, we developed a self-assembling nanovaccine to protect against ZIKV infection. By displaying ZIKV zEDIII on the recombinant human heavy chain ferritin (rHF) cage, we created zEDIII-rHF nanoparticles. Immunization of mice with zEDIII-rHF nanoparticles in the absence of an adjuvant induced robust immune responses, including humoral and cellular immune responses. Vaccination with zEDIII-rHF nanoparticles also conferred complete protection against lethal infection with ZIKV and avoided ADE of infection with a heterologous flavivirus (i.e., DENV). Our study provides an effective and safe nanovaccine against ZIKV.

**MATERIALS AND METHODS**

**Viruses and Cells**
An Asian-lineage ZIKV strain (ZIKV SZ-WIV01 GenBank: KU963796.1) was provided by the China Centre for General Virus Culture Collection (CCGCC) (30). ZIKV was propagated in Vero cells and quantified by the TCID50. Vero cells (CCL-81, ATCC) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA), 100 U/ml penicillin and 100 µg/ml streptomycin and maintained in 5% CO2 at 37°C. THP-1 cells (TIB-202, ATCC) were obtained from Professor Hanzhong Wang at the Wuhan Institute of Virology, Chinese Academy of Sciences. THP-1 cells were cultured in Roswell Park Memorial Institute medium (RPMI-1640; Gibco, Carlsbad, CA, USA) containing 10% FBS (Gibco, Carlsbad, CA, USA), 100 U/ml penicillin and 100 µg/ml streptomycin and maintained in 5% CO2 at 37°C (19).

**Generation of Vectors Expressing zEDIII-rHF**
pET28a-zEDIII-rHF was constructed using the zEDIII (SZ-WIV01) sequence and recombinant human heavy chain ferritin sequence (rHF, Gene ID: 2495). zEDIII-rHF was expressed in E. coli and purified with a nickel column that recognizes the 6-His-tag. The protein was further purified via Size Exclusion Chromatography (GE Healthcare, Uppsala, Sweden) on a Superose 6 column. The purified protein was quantified by a BCA protein assay kit (Beyotime, China), and the endotoxin concentration was tested with the ToxinSensor Single Tests Kit (GenScript, USA).

**SDS-PAGE, Western Blotting, TEM, and DLS**
SDS-PAGE and western blotting were used to characterize the size, identity, and purity of recombinant zEDIII-rHF. The antibody was an anti-zEDIII antibody (Sino Biological Cat: 40543-R101).

The shape and size of zEDIII-rHF and rHF particles were characterized by using transmission electron microscopy (TEM) (FEI Tecnai G220 TWIN electron) and dynamic light scattering (DLS) (Zetasizer Nano ZS ZEN3600, Malvern Instruments Ltd.). For the TEM, samples were absorbed onto carbon–coated copper grids for two minutes, and then were negatively stained with 2.0% phosphotungstic acid (PTA, PH 7.0) for ten minutes. The grids were dried in atmosphere and checked with transmission electron microscopy. Zeta potentials were measured by the Zetasizer Nano ZS ZEN3600.

**Animal Immunization**
ZIKV-adapted mice (B6.129S2-Ifnar1tm1Agt) were a gift from Professor Genhong Cheng (The University of California, Los Angeles (UCLA)) (31). Animals were raised under specific pathogen-free (SPF) conditions and fed sterile food and water. Six-week-old B6.129S2-Ifnar1tm1Agt mice were divided into 4 groups (n=5 per group). The mice in Group 1 received PBS as a
mock-immunized control. Those in Group 2 and Group 3 received 3.75 µg of zEDIII protein (zEDIII molar equivalent) or 6.25 µg of rHF nanoparticles, respectively. The mice in Group 4 received 10 µg of zEDIII-rHF protein (zEDIII molar equivalent). The primary immunization date was set as day 0. The mice were boosted on days 14 and 28. Blood samples were collected from the retro-orbital vein on days 10, 24 and 38, and sera were isolated for antibody detection with an indirect enzyme-linked immunosorbent assay (ELISA). The highest serum dilution that gave an OD450 of more than twice that of the lowest serum dilution of the PBS group was regarded as the endpoint of the antibody titer.

Flow Cytometry and ELISPOT Assays
Mice were euthanized, and the spleen was aseptically removed for in vitro splenocyte culture. Lymphocytes were isolated by using mouse lymphocyte separation medium (Dakewe, Beijing, China). Flow cytometry was used to measure the percentages of CD4+ and CD8+ T cells in splenic lymphocytes. We labeled cells with fluorophore-conjugated antibodies including anti-CD3 (APC/Cy7, Dakewe), anti-CD4 (FITC, Dakewe), and anti-CD8 (PerCP, Dakewe). An LSRFortessa flow cytometer (BD Biosciences) and FlowJo software (TreeStar) were used for data collection and analysis, respectively. ELISPOT was used to evaluate the numbers of IL-4- and IFN-γ-secreting cells. ELISPOT assay kits were used according to the manufacturer’s instructions (DKW22-2000-096/DKW22-2040-096). A total of 10^5 lymphocytes were added to each well in triplicate and stimulated with 1 µg of zEDIII.

Neutralization Assay
The PRNT_{50} was applied to measure zEDIII-specific NAbs (32). Blood samples were collected from the retro-orbital vein of mice in different groups. Serum samples were treated with 56°C water for 30 minutes. The serum samples were diluted along a gradient, mixed with 100 PFU of ZIKV in the same volume and incubated at 37°C for 1.5 h. The mixture was incubated with cells for another 1.5 h at 37°C, the supernatant was removed, and the cells were washed with PBS. A 1.25% methyl cellulose overlay was added, and the plates were incubated for 4 days in 5% CO_{2} at 37°C. Then, the cells were fixed with 4% paraformaldehyde and stained with 0.5% crystal violet. Plaque morphology and numbers were recorded after rinsing the plates with deionized water. Samples with titers of ≥10 were considered to be seropositive.

ZIKV Challenge and qRT-PCR Assays
The LD_{50} was calculated using the Reed & Muench method. To evaluate the protective effect of zEDIII-rHF nanoparticles against ZIKV, 14 days after the final immunization, each mouse was infected with 20 µl of ZIKV (10× LD_{50} dose, SZ-WIV/01) by foot pad injection. Over the next 21 days, the mice were monitored for body weight loss and survival. Body weight loss of more than 20% was considered indicative of lethality. Mice were euthanized according to the study guidelines. The viral challenge experiments were carried out in an ABSL-2 facility. Blood was collected from all mice for viremia analysis on day 3 and day 7 postinfection. The brain, testis, kidneys, spleen, and liver were collected for viral titer detection. Serum and tissue samples were obtained from mice, and total RNA was extracted with an RNA extraction reagent kit (Magen Cat: R4173-03). A universal pair of primers (forward primer: 5’-AGGATCATAGGTGATGAAAGAAGT-3’ and reverse primer: 5’-CTGTGGACTGATTGGTGTC-3’) was used to amplify ZIKV (33). All qRT-PCR assays were performed with the One-step TB Green PrimeScript™ PLUS RT-PCR Kit (TaKaRa, Code No. RR096A) on a CFX96 Touch real-time PCR detection system (Bio-Rad).

ADE Assays
DENV-2 challenge was carried out as previously described, and blood samples were collected for RT-PCR analysis on day 3 and day 7 post infection. A universal pair of primers (forward primer: 5’-GAAGACATTGACTGTTGCTGAA-3’ and reverse primer: 5’-CGATGGTTCCACGCCCTTCC-3’) was used to amplify DENV-2 (34). THP-1 cells were treated with 5 ng/ml phorbol 12-myristate 13-acetate (PMA) and induced to differentiate into macrophages for the ADE experiment. Immunized mouse sera were obtained, treated by heat inactivation, mixed with DENV-2 and incubated for 1 h at 37°C. Then, the mixture was added to THP-1 cells that expressed an Fc-γ receptor and incubated for four days. The cell supernatant was collected at the same time every day to quantify the DENV-2 RNA titer.

Statistical Analysis
The survival rate differences among the different groups were analyzed by the Kaplan-Meier method. One-way analysis of variance (ANOVA) was used to compare differences among the groups. All data are shown as the mean ± SD. P values <0.05 were considered significant.

RESULTS
Construction and Characterization of ZIKV zEDIII-rHF Nanoparticles
To construct the nanovaccine, zEDIII was linked to the N-terminus of rHF (Figure 1A), and a nanoparticle displaying zEDIII was generated after rHF self-assembly. A diagram of the zEDIII-rHF nanoparticle is shown in Figure 1B. The zEDIII-rHF fusion protein was expressed in Escherichia coli and purified through Ni-chelating affinity chromatography and size-exclusion chromatography (SEC). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) showed that the molecular weight of zEDIII-rHF was between 35-40 kDa, while those of rHF and zEDIII were 21 kDa and 14 kDa, respectively. zEDIII-rHF and zEDIII were further identified by Western blot analysis (Figure 1E). All the proteins were purified by removal of endotoxin to ensure that there were less than 0.001 endotoxin units per microgram of protein.

Transmission electron microscopy (TEM) showed that zEDIII-rHF could self-assemble into cage-like nanoparticles (Figure 1C and Supplementary Figure 1) in the same manner as rHF nanoparticles (Figure 1D). Dynamic light scattering (DLS) analysis was also
performed to measure the diameter of self-assembled nanoparticles. The results indicated that the zEDIII-rHF cage had an average diameter of 18.07 nm, which was larger than the diameter of rHF cages (mean = 12.92 nm). This increase in nanoparticle diameter could be attributed to the presence of the exogenous protein, which indirectly reflected the modification of rHF cages (Figure 1F). We also measured the zeta potential of the zEDIII-rHF cage. As shown in Figure 1G, the zeta potential of zEDIII-rHF was -15.27 ± 1.20 mV, which was close to that of rHF (-19.83 ± 1.07 mV). This means that the display of zEDIII on the rHF cage did not affect nanoparticle stability.

ZIKV zEDIII-rHF Activates Robust Humoral and Cellular Immunity in Mice

B6.129S2-Il2rγctm1Agt mice were used for immune analysis and subsequent virus challenge experiments, as this strain is a good animal model sensitive to ZIKV infection. Mice were intramuscularly (i.m.) vaccinated with zEDIII-rHF nanoparticles (10 μg), zEDIII (3.75 μg zEDIII molar equivalent), rHF nanoparticles (6.25 μg, rHF molar equivalent), or PBS. As shown in Figure 2A, the first vaccination time was considered day 0, and booster vaccinations were administered on days 14 and 28. Blood samples were collected to determine the zEDIII-specific IgG titer on days 7, 21 and 35. The results showed that the zEDIII-specific IgG titer was significantly higher than those in the other groups (Figures 2B, C). As controls, the mice in the rHF and PBS groups did not develop a detectable PRNT50 titer (PRNT50 titer<10-fold) (Figures 2D).

We evaluated zEDIII-rHF-activated cellular immunity, and splenic lymphocyte cells were analyzed by flow cytometry. Splenic lymphocytes were obtained using a lymphocyte isolation solution for flow cytometry. Notably, the CD4+ and CD8+ T cell percentages in the zEDIII-rHF group were significantly higher than those in the other groups (Figure 3A). As shown in Figures 3B, C, we further evaluated zEDIII-specific interleukin (IL)-4 and interferon-gamma (IFN-γ) secreting lymphocyte numbers in the spleen with a cytokine enzyme-linked immunospot (ELISPOT) assay. The lymphocyte numbers in the zEDIII-rHF group (IL-4: 50 ± 6/10⁶ cells, IFN-γ: 335 ± 40/10⁶ cells) were significantly higher than those in the other groups. No significant differences were observed between the rHF or zEDIII group and the PBS group. In the zEDIII-rHF group, the IFN-γ-secreting lymphocyte numbers were much higher than the IL-4-secreting lymphocyte numbers.
FIGURE 2 | Humoral immunity induced by zEDIII-rHF in mice. (A) Scheme for immunization, virus challenge and sampling. (B) ELISA detection of zEDIII-specific IgG in sera after each immunization, n = 5. (C) Serum neutralizing antibody titers. Samples were diluted in a twofold gradient. (D) Number of viral plaques in Vero cell cultures (Vero cells were prepared in advance in a 24-well plate, and the ZIKV dose was 100 PFU). The data in 2b and 2c are shown as the mean and standard deviation (mean ± SD) analyzed by Student’s t-test; *P < 0.05, **P < 0.01. In (B), the dotted line represents the limit of detection (LOD), which is the lowest dilution of the positive sample.

FIGURE 3 | Cellular immunity induced by zEDIII-rHF in mice. Cellular immune responses were assessed on day 28 after the second booster immunization. (A) The percentages of CD4+ and CD8+ T cells in the spleen were determined by flow cytometry. (B) IL-4-secreting lymphocytes in the spleen, n = 3. (C) IFN-γ-secreting lymphocytes in the spleen were identified via an ELISPOT assay, n = 3. The data in 3a-3c are shown as the mean and standard deviation (mean ± SD) analyzed by Student’s t-test; *P < 0.05, **P < 0.01.
Protective Efficacy of zEDIII-rHF Nanoparticles Against ZIKV in Mice

Two weeks after final immunizations, B6.129S2-Ifnar1tm1Agt mice were challenged with 20 µl of ZIKV (SZ-WIV01, 10×50% lethal dose (LD50)) by foot pad injection. Body weight loss and survival data were collected for the next 21 days. Mice with body weight loss over 20% were assumed to be fatally infected and euthanized according to the study guidelines. Notably, in the zEDIII-rHF group, the weight of the mice recovered after a slight drop in body weight (Figure 4A), and all the mice in this group survived until the end point. (Figure 4B). Mice in the other groups, including the zEDIII group, died within 14 days postinfection, with body weight losses greater than 20%. Viremia was examined on day 3 and day 10 after virus challenge by analyzing serum. Figure 4C shows that on day 3 postchallenge, a low titer of ZIKV RNA was detected in the zEDIII-rHF group, and this titer was significantly lower than those of the other groups. At day 10 postchallenge, almost no ZIKV RNA was detected in the zEDIII-rHF group, while high titers of ZIKV RNA (10^6 copies/ml) could be detected in the control groups (Figure 4D).

The viral loads in different organs were also examined on day 7 after ZIKV challenge. Viral RNA was extracted from organs and measured by quantitative real-time PCR (qRT-PCR). As shown in Figure 5A, in the zEDIII-rHF group, the viral RNA titers were undetectable in the brain, spleen, liver, and testis, and only a very low titer could be detected in the kidneys. In contrast, high titers of viral RNA were detected in these organs in the other groups. ZIKV infection causes cephalitis and cephalomeningitis. Thus, histopathological analysis of brain tissue sections was further carried out post-challenge. As shown in Figure 5B, no obvious disease symptoms could be detected in the brain of zEDIII-rHF-vaccinated mice. In contrast, mice in the zEDIII, rHF and PBS groups developed severe cephalitis and cephalomeningitis symptoms, congestion and inflammatory cuffs in small blood vessels were evident within the cerebral parenchyma, and cell shedding occurred in the cerebral cortex. This indicated that zEDIII-rHF vaccination could improve resistance to brain pathological symptoms caused by ZIKV infection.

zEDIII-rHF Elicited an Immune Response Without ADE Activity for DENV-2 Infection

A key concern in the development of ZIKV vaccines is the risk of ADE of infections by heterologous flaviviruses (e.g., DENV). Therefore, we investigated whether the zEDIII-rHF nanoparticle-elicited immune response has ADE activity for DENV-2 infection. First, ADE of DENV-2 TSV-01 infection was examined in THP-1 cells with high expression of a specific Fc receptor. DENV-2 TSV-01 was mixed with diluted serum from vaccinated mice and inoculated into THP-1 cell cultures. Following incubation, viral RNA was detected by qRT-PCR. The result is shown in Figure 6A. The DENV-2 RNA level increased with time, but there were no significant differences between the zEDIII-rHF-vaccinated group and the other groups. This meant that the zEDIII-rHF nanoparticle-elicited antibodies did not enhance DENV-2 infection of THP-1 cells. Additionally, after zEDIII-rHF vaccination, mice were challenged with 100 µl of DENV-2 (10^3 50% tissue culture infectious dose (TCID50)) by intraperitoneal injection (35).
Body weight loss and survival data were collected for the next 14 days (Figures 6B, C). Mice exhibiting body weight loss over 20% were assumed to be fatally infected and euthanized. The results showed that the body weight of mice in the zEDIII-rHF group showed the same trend as that in the zEDIII, rHF and PBS control groups. There were no significant differences in body weight loss or the survival rate between the zEDIII-rHF group and the other control groups. Mouse sera were collected on day 3 and day 7 after DENV-2 challenge to examine viremia. The results showed that the viral titers of DENV-2 in the zEDIII-rHF group were comparable to those in the zEDIII, rHF and PBS control groups (Figures 6D, E). zEDIII-rHF vaccination did not promote DENV-2 replication in mice. Taken together, these results showed that zEDIII-rHF elicited an immune response that did not cause ADE of DENV-2 infection.

DISCUSSION

In view of the ZIKV epidemic and its clinical burden, there is an urgent need to develop an effective ZIKV vaccine. Herein, we developed a nanovaccine by displaying zEDIII on self-assembled rHF nanoparticle. The zEDIII-rHF nanovaccine combined the advantages of the ZIKV antigen zEDIII and the ferritin nanoplatform. Our results showed that zEDIII-rHF nanoparticles induced robust humoral and cellular immune responses, conferred complete protection, and did not induce ADE of DENV-2 infection.

zEDIII is the domain of the ZIKV E protein, which can induce host antibody responses with neutralizing activity (36). More importantly, zEDIII-specific antibodies do not show ADE activity, while ZIKV E protein domain I/II (zEDI/zEDII)-specific antibodies induces ADE activity which leads to enhancement of DENV infection (37). Thus, zEDIII is a promising vaccine candidate that is better than other forms, including E protein subunit vaccines (38, 39). However, the immunogenicity of zEDIII is relatively low, and zEDIII immunization could not control viremia or protect mice against ZIKV infection (40). In our experiment, all of the mice immunized with zEDIII at a dose comparable to the dose achieved by zEDIII-rHF nanoparticle administration died following ZIKV challenge (Figure 4C). Notably, zEDIII-rHF
immunization completely protected mice against lethal ZIKV challenge. In zEDIII-rHF-immunized mice, there was also no cephalitis or other disease symptoms, and almost no viral RNA was detected at 7 days after ZIKV challenge. These results are amazing, making the approach of combining zEDIII with the rHF nanoplatform noteworthy.

The high protective efficiency of zEDIII-rHF nanoparticles should be attributed to their induction of robust immune responses. In our study, zEDIII-rHF evoked a high level of zEDIII-specific IgG, which has been demonstrated to play an important role in protective immunity (6, 41, 42). In the absence of any adjuvant, 10 µg of zEDIII-rHF elicited high zEDIII-specific IgG (log titer >4.5) and ZIKV-specific NAb titers (PRNT50 titer >160). In contrast, zEDIII elicited lower zEDIII-specific IgG and NAb titers. These results showed that displaying the zEDIII antigen on the ferritin nanoparticle significantly enhanced the immunogenicity of this antigen. More excitingly, zEDIII-rHF evoked a robust cellular immune response. In our experiment, zEDIII-rHF vaccination elicited high levels of CD4+ and CD8+ T cells. It has been reported that the ZIKV-specific CD4+ T cell response is critical for B cell activation and subsequent antibody maturation, playing a key role in resistance to primary ZIKV infection (43–45). CD8+ T cells protect the body against ZIKV infection mainly via cytolytic activity to kill infected cells and decrease virus-induced lymphocyte infiltration into the central nervous system (46–48). The strong CD8+ T cell response most likely contributed to eliminating virus-infected cells and preventing brain disease development. These findings should be of great significance in efforts to resist ZIKV infection and reduce symptoms.

In our study, zEDIII-rHF immunization induced significantly higher numbers of IFN-γ- and IL-4-secreting lymphocytes in the spleen of mice than did control immunizations. This indicated that T cell responses including Th1-type and Th2-type responses were efficiently induced by zEDIII-rHF nanoparticles. There were many more IFN-γ-secreting lymphocytes than IL-4-secreting lymphocytes, indicating that zEDIII-rHF nanoparticles induced Th1 type-biased responses (49). The Th1 response has been shown to be effective and preferable for controlling viral infection (50, 51), which provides a further explanation for the strong protection mediated by zEDIII-rHF vaccination. Notably, in our experiment, zEDIII without an adjuvant could not evoke T cell responses, although a certain level of zEDIII-specific IgGs could be induced, which could be one of the reasons why zEDIII did not protect against lethal ZIKV challenge.

zEDIII-rHF immunization did not show ADE activity for DENV-2 infection. ADE is an important concern for the development of vaccines against ZIKV and other flaviviruses. Abrogating or minimizing ADE has been pursued but is extremely challenging. ADE occurs because cross-reactive but subneutralizing antibodies facilitate viral binding and entry into Fc receptor-bearing cells and increase the virulence of infectivity (52). It has been reported that antibodies against EDIII/II are cross-reactive and poorly neutralizing and can mediate heterologous ADE (53). Most current ZIKV vaccine candidates, such as live attenuated ZIKV and inactivated virus, and candidates based on ZIKV prM-E use the full-length ZIKV E protein, and thus, they have the risk of inducing ADE of heterologous flavivirus infections (54). Fortunately, antibodies against the zEDIII epitope are ZIKV-specific and neutralizing and thus do not induce ADE (16, 39). Indeed, in our study, zEDIII-rHF vaccination induced ZIKV-specific NAb and did not exhibit ADE activity for DENV-2 infection. Therefore, the
zEDIII-rHF nanoparticle provides a good vaccine candidate to abrogate ADE, which makes great progress in the safety of vaccines for ZIKV and other flaviviruses.

As a kind of recombinant nanoparticle, zEDIII-rHF can be easily produced in large quantities in E. coli. This provides another advantage for the zEDIII-rHF nanoparticle. The nanoparticle eliminates the need to produce viruses or virus-like particles (VLPs) in mammalian cells, and its robust production makes it competitive in industrial and commercial applications. In addition, during vaccination, no side effects, such as changes in body weight, mobility, or fur, were found in zEDIII-rHF-immunized mice. No callosity or ulceration was observed at the injection site. The absence of any additional adjuvants during the immunization process also greatly reduces the risk of allergic reactions (55). At present, some ferritin carrier vaccine candidates have been shown to be safe and immunogenic in clinical trials (NCT03186781 & NCT03814720) (56). These results demonstrate that ferritin-based vaccines are safe and offer hopeful prospects for the use of the zEDIII-rHF nanoparticle in biomedical applications. Thus, our new zEDIII-rHF nanovaccine shows superior properties including high immunity, complete protection, lack of ADE and robust production.

CONCLUSIONS

We investigated a novel nanovaccine comprising ZIKV zEDIII assembled on ferritin nanoparticles. The zEDIII-rHF nanoparticle formulation induced strong humoral and cellular immune responses in the absence of any adjuvant and conferred complete protection against lethal ZIKV infection. Additionally, zEDIII-rHF immunization did not induce ADE of DENV-2 infection. The high immunity and protection of zEDIII-rHF, its lack of ADE and robust production indicate that zEDIII-rHF is a promising vaccine candidate against ZIKV.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

REFERENCES

1. Slavov SN, Otaguiri KK, Kashima S, Covas DT. Overview of Zika Virus (ZIKV) Infection in Regards to the Brazilian Epidemic. Braz J Med Biol Res (2016) 49(5):e5420. doi: 10.1590/1414-431X20165420
2. Song BH, Yun SI, Woolley M, Lee YM. Zika Virus: History, Epidemiology, Transmission, and Clinical Presentation. J Neuroimmunol (2017) 308:50–64. doi: 10.1016/j.jneuroim.2017.03.001
3. Musso D, Bossin H, Mallet HP, Besnard M, Broult J, Baudouin L, et al. Zika Virus in French Polynesia 2013-14: Anatomy of a Completed Outbreak. Lancet Infect Dis (2018) 18(5):e172–82. doi: 10.1016/S1473-3099 (17)30446-2
4. Hoen B, Schaub B, Funk AL, Ardillon V, Bouillard M, Cabié A, et al. Pregnancy Outcomes After ZIKV Infection in French Territories in the Americas. N Engl J Med (2018) 378(11):985–94. doi: 10.1056/NEJMoa1709481
5. Shan C, Muruato AE, Nunes BTD, Luo H, Xie X, Medeiros DBA, et al. A Live-Attenuated Zika Virus Vaccine Candidate Induces Sterilizing Immunity in Mouse Models. Nat Med (2017) 23(6):763–7. doi: 10.1038/nm.4322
6. Abbink P, Larocca RA, de la Barrera RA, Bricault CA, Mosley ET, Boyd M, et al. Protective Efficacy of Multiple Vaccine Platforms Against Zika Virus Challenge in Rhesus Monkeys. Science (2016) 353(6304):1129–32. doi: 10.1126/science.aah6157
7. Wilder-Smith A, Vannice K, Durbin A, Hombach J, Thomas SJ, Thevarjan I, et al. Zika Vaccines and Therapeutics: Landscape Analysis and Challenges Ahead. BMJ Med (2018) 16(1):84. doi: 10.1186/s12916-018-1067-x
8. Li A, Yu J, Lu M, Ma Y, Attia Z, Shan C, et al. A Zika Virus Vaccine Expressing Premembrane-Envelope-NS1 Polyprotein. Nat Commun (2018) 9 (1):3067. doi: 10.1038/s41467-018-05276-4
9. Gaudinski MR, Kouser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS, et al. Safety, Tolerability, and Immunogenicity of Two Zika Virus DNA Vaccine Candidates in Healthy Adults: Randomised, Open-Label, Phase 1

ETHICS STATEMENT

The animal study was reviewed and approved by The Animal Care Committee of Wuhan Institute of Virology.

AUTHOR CONTRIBUTIONS

ZC conceived and designed the project; HR, MQ, JP, YS and BZ performed the experiments; HR, JG, XZ, and WL analyzed the data; and HR and ZC wrote the paper. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (No. XDB29050201), the National Natural Science Foundation of China (Nos. 31925025, 91743108, and 21727816) and the Key Research Project of Frontier Science of the Chinese Academy of Sciences.

ACKNOWLEDGMENTS

We thank Professor Genhong Cheng at the University of California, Los Angeles (UCLA) for providing ZIKV-adapted mice (B6.129S2–Ifnar1tm1Agg). We also thank Professor Hanzhong Wang at the Wuhan Institute of Virology for providing the THP-1 cell support. Many thanks to Ding Gao, Guibo Rao, and Pei Zhang of the Core Facility and Technical Support, Wuhan Institute of Virology for their technical support in transmission electron microscopy. We also thank Xuefang An of the Animal Resource Center, Wuhan Institute of Virology, Chinese Academy of Sciences, for support in animal experiments.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.905431/full#supplementary-material
Clinical Trials. Lanet (2018) 391(1026):552–62. doi: 10.1016/S0140-6736(17)31055-7

10. Haque A, Ram AB. Efforts at COVID-19 Vaccine Development: Challenges and Successes. Vaccines (Basel) (2020) 8(4):739. doi: 10.3390/vaccines8040739

11. Heinz FX, Stasny K. The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunopathology. Microbiol Mol Biol Rev (2017) 81(1):e00055-16. doi: 10.1128/MMBR.00055-16

12. Shi Y, Dai L, Song H, Gao GF. Structures of Zika Virus E & NS1: Relations With Virus Infection and Host Immune Responses. Adv Exp Med Biol (2018) 1062:77–87. doi: 10.1007/978-981-10-8727-1_6

13. Tirado SM, Yoon KJ. Antibody-Dependent Enhancement of Virus Infection and Disease. Viral Immunol (2003) 16(1):69–86. doi: 10.1089/0898664031250008561

14. Shi Y, Dai L, Zhang Q, Xu M, Zhang H, Gu D, et al. Isolation and Characterization of Zika Virus Imported to China Using C6/36 Mosquito Cells. Virol Sin (2016) 31(2):176–9. doi: 10.1007/s12250-016-3778-5

15. Müller U, Steinhoff U, Reis LF, Hemmi S, Pavlović J, Zinkernagel RM, et al. Functional Role of Type I and Type II Interferons in Antiviral Defense. Science (1994) 264(5167):1918–21. doi: 10.1126/science.8009221

16. Li K, P X, Wang T, Tan Z, Luo D, Miao Y, et al. Zika Virus Attenuation by Codon Pair Deoptimization Induces Immune Stimulatory in Mice Mouse. J Virol (2018) 92(17):e00701-18. doi: 10.1128/JVI.00701-18

17. Xu MY, Liu SQ, Deng CL, Zhang QY, Zhang B. Detection of Zika Virus by SYBR Green One-Step Real-Time RT-PCR. J Virol Methods (2016) 236:93–7. doi: 10.1016/j.jvireme.2016.07.014

18. Chen H, Parimalalagan M, Lai YL, Lee KS, Koay ES, Hapuarachchi HC, et al. Development and Evaluation of a SYBR Green-Based Real-Time Multiplex RT-PCR Assay for Simultaneous Detection and Serotyping of Dengue and Chikungunya Viruses. J Mol Diagn (2015) 17(6):722–8. doi: 10.1016/j.jmoldx.2015.06.008

19. Kotaki T, Kurosu T, Grinyo-Escuer A, Davidson E, Churrotin S, Okabayashi T, et al. An Affinity-Matured Human Monoclonal Antibody Targeting Fusion Loop Epitope of Dengue Virus With In Vivo Therapeutic Potency. Sci Rep (2021) 11(1):12987. doi: 10.1038/s41598-021-83601-0

20. Tai W, He L, Wang Y, Sun S, Zhao G, Luo C, et al. Critical Neutralizing Fragment of Zika Virus EDIII Elicits Cross-Neutralization and Protection Against Divergent Zika Viruses. Emerg Microbes Infect (2018) 7(1):7. doi: 10.1016/j.evimicro.2017.05.008

21. Dai L, Xu K, Li J, Huang Q, Song J, Han Y, et al. Protective Zika Vaccines Engineered to Eliminate Enhancement of Dengue Infection via Immunodominance Switch. Nat Immunol (2021) 22(8):958–68. doi: 10.1038/s41590-021-00966-6

22. Qi J, He Y, Shen L, Yu W, Hu T. Congjugation of Hemoglobin and Mamm Markedly Improves the Immunogenicity of Domain III of the Zika Virus E Protein: Structural and Immunological Study. Bioconjug Chem (2021) 32(2):328–38. doi: 10.1021/acs.bioconjchem.0c00700

23. Shukla R, Shamnugam RK, Ramsamy V, Arora U, Batra G, Acklin JA, et al. Zika Virus Envelope Nanoparticle Antibodies Protect Mice Without Risk of Disease Enhancement. EBioMedicine (2020) 54:102738. doi: 10.1016/j.ebiomed.2020.102738

24. Lopez-Camacho C, De Lorenzo G, Solor-Camps JL, Dowall S, Abbink P, Larroca RA, et al. Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA Protein, and ChAdOx1 Adenoviral-Vected Vaccines. Vaccines (Basel) (2020) 8(2):307. doi: 10.3390/vaccines8020307

25. Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, et al. Modified mRNA Vaccines Protect Against Zika Virus Infection. Cell (2017) 169(1):176. doi: 10.1016/j.cell.2017.02.017

26. Sumathy K, Kulkarni B, Gondu RK, Ponnuru SK, Bonguram N, Eligetti R, et al. Protective Efficacy of Zika Vaccine in AG129 Mouse Model. Sci Rep (2017) 7:46375. doi: 10.1038/srep46375

27. Lucas CGO, Kitoko JZ, Ferreira FM, Suzzart VG, Papa MP, Coelho SVA, et al. Critical Role of CD4(+) T Cells and IFN-Gamma Signalling in Antibody-Mediated Resistance to Zika Virus Infection. Nat Commun (2018) 9(1):3136. doi: 10.1038/s41467-018-05852-7

28. Perez P, Martin-Acubes MA, Poderoso T, Lázaro-Frias A, Saiz JC, Sorzano COS, et al. The Combined Vaccination Protocol of DNA/MAV Expressing Zika Virus Structural Proteins as Efficient Inducer of T and B Cell Immune Responses. Emerg Microbes Infect (2021) 10(1):1441–56. doi: 10.1080/22221751.2021.1951624

29. Elong Ngono A, Syed T, Nguyen AV, Regla-Nava JA, Susantonio M, Spasova D, et al. CD8(+) T Cells Mediate Protection Against Zika Virus Induced by an NS3-Based Vaccine. Sci Adv (2020) 6(45):eabb2154. doi: 10.1126/sciadv.abb2154

30. Cox F, van der Fits L, Abbink P, Larroca RA, van Huizen E, Saad S, et al. Adenoviral Vector Type 26 Encoding Zika Virus (ZIKV) M-Env Antigen Induces Humoral and Cellular Immune Responses and Protects Mice and Nonhuman Primates Against ZIKV Challenge. Plos One (2018) 13(8): e0202820. doi: 10.1371/journal.pone.0202820
47. Pérez P, Marín M Q, Lázaro-Frias A, Jiménez de Oya N, Blázquez AB, Escríbano-Romero E, et al. A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice. Sci Rep (2018) 8(1):17385. doi: 10.1038/s41598-018-35724-6

48. Huang H, Li S, Zhang Y, Han X, Jia B, Liu H, et al. CD8(+) T Cell Immune Response in Immunocompetent Mice During Zika Virus Infection. J Virol (2017) 91(22):e00900-17. doi: 10.1128/JVI.00900-17

49. Zhao K, Sun B, Shi C, Sun Y, Jin Z, Hu G. Intranasal Immunization With O-2'-Hydroxypropyl Trimethyl Ammonium Chloride Chitosan Nanoparticles Loaded With Newcastle Disease Virus DNA Vaccine Enhances Mucosal Immune Response in Chickens. J Nanobiotechnol (2021) 19(1):240. doi: 10.1186/s12951-021-00983-5

50. Wen J, Shresta S. T Cell Immunity to Zika and Dengue Viral Infections. J Interferon Cytokine Res (2017) 37(11):475–9. doi: 10.1089/jir.2017.0106

51. Wen J, Wang YT, Valentine KM, Dos Santos Alves RP, Xu Z, Regla-Nava JA, et al. CD4(+) T Cells Cross-Reactive With Dengue and Zika Viruses Protect Against Zika Virus Infection. Cell Rep (2020) 31(4):107566. doi: 10.1016/j.celrep.2020.107566

52. Bournazos S, Gupta A, Ravetch JV. The Role of IgG Fc Receptors in Antibody-Dependent Enhancement. Nat Rev Immunol (2020) 20(10):633–43. doi: 10.1038/s41577-020-00410-0

53. Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, et al. Specificity, cross-Reactivity, and Function of Antibodies Elicited by Zika Virus Infection. Science (2016) 353(6301):823–6. doi: 10.1126/science.aaf8505

54. Slon-Campos JL, Dejnirattisai W, Jagger BW, López-Camacho C, Wongwiwat W, Durnell LA, et al. A Protective Zika Virus E-Dimer-Based Subunit Vaccine Engineered to Abrogate Antibody-Dependent Enhancement of Dengue Infection. Nat Immunol (2019) 20(10):1291–8. doi: 10.1038/s41590-019-0477-z

55. Tregoning JS, Russell RF, Künneke E. Adjuvanted Influenza Vaccines. Hum Vaccin Immunother (2018) 14(3):550–64. doi: 10.1080/21645515.2017.1415684

56. Powell AE, Zhang K, Sanyal M, Tang S, Weidenbacher PA, Li S, et al. A Single Immunization With Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses Against SARS-CoV-2 in Mice. ACS Cent Sci (2021) 7(1):183–99. doi: 10.1021/acscentsci.0c01405

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Rong, Qi, Pan, Sun, Gao, Zhang, Li, Zhang and Cui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.